Search
Seletracetam
go.drugbank.com/drugs/DB05885InvestigationalIt binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability.
Ibuzatrelvir
go.drugbank.com/drugs/DB19451InvestigationalIbuzatrelvir is under investigation in clinical trial NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized but
Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalBy inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and
Tifuvirtide
go.drugbank.com/drugs/DB05413InvestigationalIt has received fast-track designation from the FDA and is in Phase I/II clinical testing.
Latrunculin A
go.drugbank.com/drugs/DB02621InvestigationalLatrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer.
Synonyms: (4R)-4-[(1R,4Z,8E,10Z,12S,15R,17R)-17-hydroxy-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]-1,3-thiazolidin-2-oneDialyzable leukocyte extract
go.drugbank.com/drugs/DB16530InvestigationalTransferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator.
Ala-geninthiocin
go.drugbank.com/drugs/DB15657ExperimentalAla-geninthiocin is a novel thiopeptide antibacterial compound derived from marine _Streptomyces_ species.
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Parecoxib
go.drugbank.com/drugs/DB08439ApprovedInvestigationalA letter of non-approval for parecoxib was issued by the FDA in 2005.
Synonyms: N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamideIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.